Stable-state midrange-proadrenomedullin level is a strong predictor of mortality in patients with COPD

Chest

Volumn 145, Issue 3, 2014, Pages 534-541

  Zuur Telgen, Maaike C ^a   Brusse Keizer, Marjolein G J ^a   VanderValk, Paul D L P M ^a   Van Der Palen, Job ^b   Kerstjens Dr , Huib A M ^c,d   Hendrix Dr , M G Ron ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Groningen Research Institute for Asthma and COPD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROADRENOMEDULLIN; PROCALCITONIN; ADRENOMEDULLIN; MID-REGIONAL PRO-ADRENOMEDULLIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

AGED; AIRWAY OBSTRUCTION; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; PATIENT ACUITY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY; SPUTUM;

ADRENOMEDULLIN; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; PATIENT ACUITY; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SPUTUM;

EID: 84896753008     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1063     Document Type: Article

References (41)

1. Murray CJ, Lopez AD.Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.Lancet.1997; 349 (9063):1436-1442
2. Sapey E, Stockley RA.COPD exacerbations. 2: aetiology.Thorax.2006; 61 (3):250-258
3. Anthonisen NR, Wright EC, Hodgkin JE.Prognosis in chronic obstructive pulmonary disease.Am Rev Respir Dis.1986;133 (1):14-20
4. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF.Body composition and mortality in chronic obstructive pulmonary disease.Am J Clin Nutr.2005; 82 (1):53-59
5. Nishimura K, Izumi T, Tsukino M, Oga T.Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.Chest.2002; 121 (5):1434-1440
6. Cote CG, Casanova C, Marín JM, et al.Validation and comparison of reference equations for the 6-min walk distance test.Eur Respir J.2008; 31 (3):571-578
7. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T.Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status.Am J Respir Crit Care Med.2003; 167 (4):544-549
8. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R.Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.Thorax.2005; 60 (11):925-931
9. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA.Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.Thorax.2002; 57 (10):847-852
10. Celli BR, Cote CG, Marin JM, et al.The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med.2004; 350 (10):1005-1012
11. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X.Systemic effects of chronic obstructive pulmonary disease.Eur Respir J.2003; 21 (2):347-360
12. Seemungal TA, Wedzicha JA. Acute exacerbations of COPD: the challenge is early treatment.COPD.2009; 6 (2):79-81
13. Puhan MA, Garcia-Aymerich J, Frey M, et al.Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and theADO index.Lancet.2009; 374 (9691):704-711
14. Hurst JR, Donaldson GC, Perera WR, et al.Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.Am J Respir Crit Care Med.2006; 174 (8):867-874
15. Koutsokera A, Stolz D, Loukides S, Kostikas K.Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge.Chest.2012; 141 (2):396-405
16. Lacoma A, Prat C, Andreo F, et al.Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis.2011; 6:157-169
17. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma proadrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.Chest.2008; 134 (2):263-272
18. Prat C, Domínguez J, Andreo F, et al.Procalcitonin and neopterin correlation with aetiology and severity of pneumonia.J Infect.2006; 52 (3):169-177
19. Bello S, Lasierra AB, Mincholé E, et al.Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.Eur Respir J.2012; 39 (5):1144-1155
20. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD.Chest.2007; 131 (4): 1058-1067
21. Linscheid P, Seboek D, Zulewski H, Keller U, Müller B.Autocrine/paracrine role of infl ammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue.Endocrinology. 2005; 146 (6):2699-2708
22. Yoshibayashi M, Kamiya T, Kitamura K, et al.Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients, 20 years of age.Am J Cardiol.1997; 79 (11):1556-1558
23. Cheung BM, Hwang IS, Li CY, et al.Increased adrenomedullin expression in lungs in endotoxaemia.J Endocrinol.2004; 181 (2):339-345
24. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T.Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma.FEBS Lett.1994; 338 (1):6-10
25. Struck J, Tao C, Morgenthaler NG, Bergmann A.Identification of an adrenomedullin precursor fragment in plasma of sepsis patients.Peptides.2004; 25 (8):1369-1372
26. Morgenthaler NG, Struck J, Alonso C, Bergmann A.Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay.Clin Chem.2005; 51 (10) :1823-1829
27. Vizza CD, Letizia C, Sciomer S, et al.Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with endstage pulmonary disease.Regul Pept.2005; 124 (1-3):187-193
28. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P.Infl ammatory responses predict long-term mortality risk in community-acquired pneumonia.Eur Respir J.2011; 37 (6):1439-1446
29. von Haehling S, Filippatos GS, Papassotiriou J, et al.Midregional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.Eur J Heart Fail.2010; 12 (5):484-491
30. Janssen DJ, Spruit MA, Schols JM, et al.Predicting changes in preferences for life-sustaining treatment among patients with advanced chronic organ failure.Chest.2012; 141 (5):1251-1259
31. Pauwels RA, Buist AS, Calverley PM, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary.Am J Respir Crit Care Med.2001; 163 (5): 1256-1276
32. Telgen MC, Brusse-Keizer MG, van der Valk PD, van der Palen J, Kerstjens HA, Hendrix MG.Impact on clinical decision making of quality control standards applied to sputum analysis in COPD.Respir Med.2011; 105 (3):371-376
33. Jougasaki M, Burnett JC Jr.Adrenomedullin: potential in physiology and pathophysiology.Life Sci.2000; 66 (10):855-872
34. Behnes M, Papassotiriou J, Walter T, et al.Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.Clin Chem Lab Med.2008; 46 (2):204-211
35. Khan SQ, O'Brien RJ, Struck J, et al.Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute MyocardialInfarction Peptide) study.J Am Coll Cardiol.2007; 49 (14):1525-1532
36. Mahler DA, Wells CK.Evaluation of clinical methods for rating dyspnea.Chest.1988; 93 (3):580-586
37. Huber-Carol C, Balakrishnan N, Nikulin MS, Mesbah M, eds. Goodness-of-Fit Tests and Model Validity.Boston, MA: Birkhäuser; 2002;273-277
38. Kamoi H, Kanazawa H, Hirata K, Kurihara N, Yano Y, Otani S. Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages.Biochem Biophys ResCommun.1995; 211 (3):1031-1035
39. Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H.Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells.FEBS Lett.1995; 369 (2-3):311-314
40. Kohno M, Hanehira T, Hirata K, et al.An accelerated increase of plasma adrenomedullin in acute asthma.Metabolism.1996; 45 (11):1323-1325
41. Stolz D, Christ-Crain M, Bingisser R, et al.Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.Chest.2007; 131 (1):9-19